LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of MabVax Therapeutics Holdings, Inc. (“MabVax” or the “Company”) (NASDAQ: MBVX) investors concerning the Company and its officers’ possible violations of federal securities laws.
To obtain information or actively participate in the class action, please visit the MabVax page on our website at www.glancylaw.com/case/mabvax-therapeutics-holdings-inc.
On May 24, 2018, MabVax received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires the timely filing of periodic reports with the U.S. Securities and Exchange Commission. The notice was sent as a result of the delay in the filing of the Company's Quarterly Report on Form 10-Q for the period ending March 31, 2018 (the "Form 10-Q"). On this news, shares of MabVax fell significantly, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased MabVax securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.